Login to Your Account



Amgen to carry Cytokinetics HF drug into phase III

By Michael Fitzhugh
Staff Writer

Thursday, September 1, 2016

A long-awaited global phase III study of Cytokinetics Inc.'s chronic heart failure drug omecamtiv mecarbil, funded and run by partner Amgen Inc., is on track to start during the fourth quarter, the companies said.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription